{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:22:56Z","timestamp":1779888176323,"version":"3.53.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00520-023-07793-5","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:54:49Z","timestamp":1684158889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients"],"prefix":"10.1007","volume":"31","author":[{"given":"Stephanie","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Menzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"7793_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","volume":"41","author":"LK Collins","year":"2017","unstructured":"Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125\u2013128","journal-title":"Curr Probl Cancer"},{"key":"7793_CR2","doi-asserted-by":"crossref","unstructured":"Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 71:203.e201\u2013203.e212; quiz 215\u2013206","DOI":"10.1016\/j.jaad.2014.04.014"},{"key":"7793_CR3","doi-asserted-by":"crossref","unstructured":"Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 71:217.e211\u2013217.e211; quiz 227\u2013218","DOI":"10.1016\/j.jaad.2014.04.013"},{"key":"7793_CR4","unstructured":"US Department of Health and Human Services (2017). Common Terminology Criteria\nfor Adverse Events (CTCAE)\nVersion 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf.\u00a0 Accessed 1 May 2021"},{"key":"7793_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00432-016-2335-9","volume":"143","author":"TM Atkinson","year":"2017","unstructured":"Atkinson TM, Rogak LJ, Heon N, Ryan SJ, Shaw M, Stark LP, Bennett AV, Basch E, Li Y (2017) Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol 143:735\u2013743","journal-title":"J Cancer Res Clin Oncol"},{"key":"7793_CR6","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jnci\/djp386","volume":"101","author":"E Basch","year":"2009","unstructured":"Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624\u20131632","journal-title":"J Natl Cancer Inst"},{"key":"7793_CR7","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910\u2013915","journal-title":"J Clin Oncol"},{"key":"7793_CR8","doi-asserted-by":"crossref","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD, 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059","DOI":"10.1001\/jamaoncol.2015.2639"},{"key":"7793_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMp1707537","volume":"377","author":"LS Rotenstein","year":"2017","unstructured":"Rotenstein LS, Huckman RS, Wagle NW (2017) Making patients and doctors happier - the potential of patient-reported outcomes. N Engl J Med 377:1309\u20131312","journal-title":"N Engl J Med"},{"key":"7793_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197\u2013198","journal-title":"JAMA"},{"key":"7793_CR11","unstructured":"National Cancer Institute (2023). Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u00ae). https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/. Accessed 1 May 2021"},{"key":"7793_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327\u2013333","journal-title":"Am J Clin Dermatol"},{"key":"7793_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1477-7525-8-104","volume":"8","author":"EA Laugsand","year":"2010","unstructured":"Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, Klepstad P (2010) Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes 8:104","journal-title":"Health Qual Life Outcomes"},{"key":"7793_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1472-6963-13-211","volume":"13","author":"J Chen","year":"2013","unstructured":"Chen J, Ou L, Hollis SJ (2013) A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 13:211","journal-title":"BMC Health Serv Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07793-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:08:04Z","timestamp":1686388084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7793"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07793-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The MSK Research Ethics Committee has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No consent to publish is needed for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Informed consent was obtained from all individual patients included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"AM receives research funding from Incyte Corporation and Amryt Pharma; consults for ADC Therapeutics, Alira Health, Protagonist Therapeutics, OnQuality, and Janssen; and receives royalties from UpToDate. MEL has a consultant role with Johnson and Johnson, Novocure, Janssen, Novartis, Deciphera, Kintara, RBC\/La Roche Posay, Trifecta, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Roche, Oncoderm, Apricity. MEL also receives research funding from Lutris, Paxman, Novocure, OQL, Novartis and AZ, and is funded in part through the NIH\/NCI Cancer Center Support Grant P30 CA008748.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}